Items where authors include "Gladman, D"

Article

Coates, LC, Soriano, ER, Corp, N et al. (42 more authors) (2022) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nature Reviews Rheumatology, 18 (8). pp. 465-479. ISSN 1759-4790

Aydin, SZ, Bakirci, S, Kasapoglu, E et al. (8 more authors) (2020) The relationship between physical examination and ultrasonography for large entheses is best for the Achilles tendon and patellar tendon origin. Journal of Rheumatology, 47 (7). pp. 1026-1030. ISSN 0315-162X

Coates, LC orcid.org/0000-0002-4756-663X, FitzGerald, O, Merola, JF et al. (23 more authors) (2018) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. Arthritis & Rheumatology, 70 (3). pp. 345-355. ISSN 2326-5191

Cortes, A, Maksymowych, WP, Wordsworth, BP et al. (16 more authors) (2015) Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis. Annals of the Rheumatic Diseases, 74 (7). pp. 1387-1393. ISSN 0003-4967

Conference or Workshop Item

Mease, P, Helliwell, P orcid.org/0000-0002-4155-9105, Gladman, D et al. (10 more authors) (2022) Effect of Guselkumab a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients With Active PsA: Results From a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years. In: Canadian Rheumatology Association Annual Meeting, 02-05 Feb 2022, Online.

Mease, P, Helliwell, PS orcid.org/0000-0002-4155-9105, Gladman, D et al. (10 more authors) (2021) Effect of Guselkumab (TREMFYA (R)), a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients with Active PsA: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Mease, P, Helliwell, P orcid.org/0000-0002-4155-9105, Gladman, D et al. (12 more authors) (2021) Efficacy of Guselkumab on Axial-Related Endpoints in Patients with Active Psoriatic Arthritis with Imaging-Confirmed Sacroiliitis. In: Twelfth International Congress on Spondyloarthritides, 09-11 Sep 2021, Virtual.

Mease, P, Coates, L, Van den Bosch, F et al. (7 more authors) (2020) Effect of Filgotinib on the Complete Resolution of Enthesitis in Psoriatic Arthritis (PsA) Patients: 52-week Results from EQUATOR2. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.

Mease, P, Helliwell, P orcid.org/0000-0002-4155-9105, Gladman, D et al. (15 more authors) (2020) Efficacy of Guselkumab, a Monoclonal Antibody That Specifically Binds to the p19 Subunit of IL-23, on Axial-Related Endpoints in Patients with Active PsA with Imaging-Confirmed Sacroiliitis: Week-52 Results from Two Phase 3, Randomized, Double-blind, Placebo-controlled Studies. In: 37º Congresso Brasileiro de Reumatologia, 19-22 Nov 2020, Virtual.

Coates, L, Gladman, D, Van den Bosch, F et al. (10 more authors) (2020) Long-term Outcomes with Filgotinib, an Oral Selective Janus Kinase 1 Inhibitor: 100-week Data from an Open-label Extension (OLE) Study in Patients with Active Psoriatic Arthritis (PsA). In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.

Helliwell, P orcid.org/0000-0002-4155-9105, Mease, P, Kavanaugh, A et al. (9 more authors) (2020) What Influence Do Clinical Domains Other Than Arthritis Have on Composite Clinical Outcomes in Psoriatic Arthritis?: Comparison of Treatment Effects in the SEAM-PsA Trial. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.

Coates, L, Mease, P, Gladman, D et al. (8 more authors) (2020) Long-Term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study. In: British Society for Rheumatology Annual Conference 2020, 20-22 Apr 2020.

Coates, L, Mease, P, Gladman, D et al. (8 more authors) (2020) Long-term safety of filgotinib in patients with PsA: week 52 safety data from a Phase 2 open-label extension study. In: British Society for Rheumatology Annual Conference 2020, 20-22 Apr 2020, Cancelled.

Coates, L, Mease, P, Gladman, D et al. (8 more authors) (2019) Long-term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study. In: 2019 ACR/ARP Annual Meeting Minutes, 08-13 Nov 2019, Atlanta, Georgia, USA.

Coates, L, Merola, J, Mease, P et al. (10 more authors) (2019) The Performance Characteristics of Composite Measures Used in a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis. In: 2019 ACR/ARP Annual Meeting, 08-13 Nov 2019, Atlanta, Georgia, USA.

Helliwell, P, Bushmakin, A, Gladman, D et al. (5 more authors) (2019) Relationships Between Minimal Disease Activity and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies. In: 2019 ACR/ARP Annual Meeting, 08-13 Nov 2019, Atlanta, Georgia, USA.

Coates, L, Bushmakin, A, FitzGerald, O et al. (5 more authors) (2019) Relationships Between Psoriatic Arthritis Disease Activity Score and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies. In: 2019 ACR/ARP Annual Meeting, 08-13 Nov 2019, Atlanta, Georgia, USA.

Gladman, D, Coates, L, Wu, J et al. (6 more authors) (2019) Time to Response for Clinical and Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Tofacitinib, Adalimumab, or Placebo. In: 2019 ACR/ARP Annual Meeting, 08-13 Nov 2019, Atlanta, Georgia, USA.

Gladman, D, Boehncke, W-H, Gottlieb, AB et al. (7 more authors) (2019) The Effect of Guselkumab on Dactylitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis. In: Pan-American Congress of Rheumatology 2019, 27-30 Apr 2019, Quito, Ecuador.

Proceedings Paper

Helliwell, P, Lespessailles, E, Shuler, C et al. (4 more authors) (2018) Ixekizumab Provides Sustained Improvement in Signs and Symptoms in Patients with Active Psoriatic Arthritis: Two-Year Results from a Phase 3 Trial. In: Journal of Rheumatology. 73rd Annual Meeting of The Canadian-Rheumatology-Association (CRA), 21-24 Feb 2018, Vancouver, Canada. Journal of Rheumatology Publishing Co., Ltd. , pp. 998-999.